Table 4.

Final list of research priorities identified by the nominal group process

1.	Defining genetic and environmental factors, which influence the overall risk and natural history of PC
2.	Defining markers of prognosis and therapeutic responsiveness, which can facilitate the development of personalised therapies
3.	Developing a better understanding of PC tumour biology and pancreatic carcinogenesis
4.	Developing novel therapies and therapeutic strategies
5.	Validating strategies for the optimal, timely, and consistent management for all disease stages
6.	Defining the most common disease and treatment-related sequelae and identifying strategies for managing them
7.	Developing strategies to identify PC at a potentially curable stage